Cordis Corporation To Emphasize Commitment To Interventional Cardiology At 2007 American College Of Cardiology Conference
Miami Lakes, FL – Cordis Corporation will highlight its commitment to the practice of interventional cardiology at the upcoming American College of Cardiology’s 56th Annual Scientific Session (ACC.07) in New Orleans from March 24-27.
During this worldwide medical conference, cardiologists will have access to emerging and long-term clinical evidence about the CYPHER® Sirolimus-eluting Coronary Stent and new clinical data involving the use of the NOGA® XP Cardiac Navigation System, from Cordis Corporation’s Biologics Delivery Systems, for the targeted delivery of adult stem cells to the heart. In addition, Cordis will showcase the REGATTA™ Steerable Guidewire family, its latest approved cardiovascular technology to enable interventional cardiologists to improve patient care.
“ACC.07 will serve as backdrop for the presentation of important registries and randomized clinical trials – the gold standard for clinical evidence – for the CYPHER® Stent. Together, they will further clinical understanding about the CYPHER® Stent and other products that are part of the Cordis Cardiology family, such as the NOGA® XP Cardiac Navigation System,” said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Cardiology Division, Cordis Corporation.
“We welcome the opportunity to share with physicians new clinical data about the CYPHER® Stent to help them advance treatment for patients with coronary artery disease,” Dr. Kandzari added. “ACC.07 also gives us an excellent occasion to discuss with interventional cardiologists our growing portfolio of products and services designed specifically for use in the cardiac cath lab, including the recently launched REGATTA™ Guidewire family.”
During ACC.07, Cordis will present the five-year results of the SIRIUS Trial, a pivotal randomized trial that was part of the basis for the approval of the CYPHER® Stent in the United States in 2003 and the longest running U.S.-based randomized study for a drug-eluting stent. Other clinical data to be presented include three-year results of the ARTS II Study, a multi-center, prospective study comparing the CYPHER® Stent to coronary artery bypass grafting (bypass surgery) in patients with blockages in two or more vessels, an indication not approved in the United States for the CYPHER® Stent; and two-year results from the MATRIX Registry, which examines the long-term safety of the CYPHER® Stent in on-label and off-label indications.
ACC.07 will also feature the presentation of the PERMIT Study, the first randomized trial in the United States that investigates the use of a 3-D injection catheter in combination with the NOGA® XP Cardiac Navigation System to provide targeted delivery of adult stem cells, called skeletal myoblasts, for treating damaged heart tissue. The NOGA® XP Cardiac Navigation System, which was approved by the U.S. Food and Drug Administration in 2006, is an innovative 3-D imaging system and the only guided electromechanical cardiac navigation technology available to physicians for use in a wide variety of advanced medical procedures.
The dates and times for the clinical data presentations mentioned in this news release follow:
Sunday, March 25
PERMIT Study: This study involving the NOGA® XP Cardiac Navigation System will be presented by Nabil Dib, M.D., M.Sc., F.A.C.C., from the University of California/San Diego, during a late-breaking clinical trials session at 11:15 a.m. Central Daylight Savings Time (CDT).
Monday, March 26
ARTS II Study: This CYPHER® Stent study will be presented by Patrick W. Serruys, M.D., Ph.D., from Thoraxcenter, Erasmus Medical Center in The Netherlands, at 12 p.m. CDT.
MATRIX Registry: This CYPHER® Stent patient registry will be presented by George D. Dangas, M.D., Ph.D., from Columbia University Medical Center, during a late-breaking clinical trials presentation at 2:15 p.m. CDT.
Tuesday, March 27
SIRIUS Trial: This study examining the performance of the CYPHER® Stent versus bare-metal stentsin FDA-approved indications will be presented by Martin B. Leon, M.D., from Columbia University Medical Center, at 10 a.m. CDT.
The studies are embargoed until the time of the scientific presentations.
More information about the presence of Cordis at ACC.07 can be found at www.events.cordis.com.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.